Seeking Alpha
09 May 2026, 01:51 UTC · 20w ago
Verdict
Headline takes no side. We score IFRX +0.50 across two claims — strongly bullish.
+0.50strongly bullish
More positive than 71% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
InflaRx is strategically pivoting its primary development focus to izicopan for ANCA-associated vasculitis and renal diseases.
More positive than 93% of claims this week
InflaRx is expanding the therapeutic scope of izicopan to specifically target renal diseases in addition to ANCA-associated vasculitis.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 87% of claims this week
Which stocks this story touches
More positive than 71% of ticker scores this week
The company is discussing strategic focus and potential applications for its drug candidate Izicopan, indicating positive development progress.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
13h ago
−33.3%
Price is moving against the score
$1.72 vs $2.58 close before publication (May 8) · not market-adjusted
IFRX chart →
